Weidong Wei
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine
Papers in
-
- MicroRNA in disease regulation 4
- Cancer-related molecular mechanisms research 3
- Cancer, Lipids, and Metabolism 3
- Oncology 11
- PARP inhibition in cancer therapy 3
- HER2/EGFR in Cancer Research 3
- Inflammatory Biomarkers in Disease Prognosis 2
- Lung Cancer Research Studies 2
- Co-authors
- Xiaoming Xie (17 shared papers)Hailin Tang (14 shared papers)Danian Dai (9 shared papers)Yanan Kong (11 shared papers)Xinhua Xie (8 shared papers)Lu Yang (5 shared papers)Bo Chen (2 shared papers)Bo Chen (4 shared papers)
- Journals
- Journal of Cancer (4 papers)PLoS ONE (3 papers)Frontiers in Oncology (2 papers)Medical Oncology (2 papers)Theranostics (1 paper)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Weidong Wei
34 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 119
- Cancer Research 465
- Geriatrics and Gerontology 62
- Oncology 270
- Surfaces, Coatings and Films 71
- Molecular Biology 591
Countries citing papers authored by Weidong Wei
This map shows the geographic impact of Weidong Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weidong Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weidong Wei more than expected).
Fields of papers citing papers by Weidong Wei
This network shows the impact of papers produced by Weidong Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weidong Wei. The network helps show where Weidong Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Weidong Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 222 | |
| 2 | 2020 | 136 | |
| 3 | 2015 | 130 | |
| 4 | 2013 | 102 | |
| 5 | 2014 | 86 | |
| 6 | 2018 | 77 | |
| 7 | 2019 | 74 | |
| 8 | 2012 | 74 | |
| 9 | 2018 | 61 | |
| 10 | 2018 | 55 | |
| 11 | 2016 | 39 | |
| 12 | 2018 | 38 | |
| 13 | 2015 | 36 | |
| 14 | 2011 | 31 | |
| 15 | 2016 | 30 | |
| 16 | 2022 | 29 | |
| 17 | 2016 | 27 | |
| 18 | 2008 | 23 | |
| 19 | 2012 | 22 | |
| 20 | 2012 | 21 |
About Weidong Wei
Weidong Wei is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology and Structural Biology, having authored 34 papers that have together received 1.4k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (4 papers), Cancer-related molecular mechanisms research (3 papers), PARP inhibition in cancer therapy (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer, Lipids, and Metabolism (3 papers), Inflammatory Biomarkers in Disease Prognosis (2 papers), Lung Cancer Research Studies (2 papers) and Circular RNAs in diseases (2 papers). The work is most often cited by research in Cancer Research (465 citations), Geriatrics and Gerontology (62 citations), Oncology (270 citations), Surfaces, Coatings and Films (71 citations) and Molecular Biology (591 citations). Weidong Wei has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Xiaoming Xie, Hailin Tang, Danian Dai, Yanan Kong, Xinhua Xie, Lu Yang, Bo Chen, Bo Chen, Weiyu Chen and Xiaojia Huang. Their work appears in journals such as Journal of Cancer, PLoS ONE, Frontiers in Oncology, Medical Oncology and Theranostics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.